Australia - inglés - Department of Health (Therapeutic Goods Administration)

the remedy company - 58009 - lip herpes dressing - the indented purpose of the devices is to promote drying and healing of the lesions on the lips (cold sores) and to reduce pain and sensitivity of the lesion.

Filipinas - inglés - FDA (Food And Drug Administration)

unilab, inc. - lipid emulsion , amino acids , electrolytes , glucose - emulsion for intravenous infusion (iv) - (see attachment for formulation)

Australia - inglés - Department of Health (Therapeutic Goods Administration)

nutra pty ltd - 58009 - lip herpes dressing - a non-sterile fluid material intended to be applied to herpetic lesions of the lips (herpes labialis) to help protect the lesions from the external environment, reduce painful symptoms (e.g., prickly and burning sensations, itch, pain), and to facilitate lesion healing. it is in the form of a gel and is available [non-prescription] over-the-counter (otc) for home-use. after application, this device cannot be reused.

Canadá - inglés - Health Canada

trophic canada ltd. - vitamin a; vitamin e; ascorbic acid; wheat germ oil; rose hips; phosphatidyl choline; lipase - tablet - 10000unit; 100unit; 100mg; 50mg; 10mg; 10mg; 10mg - vitamin a 10000unit; vitamin e 100unit; ascorbic acid 100mg; wheat germ oil 50mg; rose hips 10mg; phosphatidyl choline 10mg; lipase 10mg - multivitamin preparations

Estados Unidos - inglés - NLM (National Library of Medicine)

pharmagel international inc - petrolatum............................48% - lip protectant • helps protect, relieve, and prevent chapped lips • helps protect from the drying effects of wind and cold weather if irritation or rash defelops and continues for more than 72 hours.

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

merit pharmaceuticals limited - lipase; amylase; protease - gastro-resistant capsule, hard - 150 milligram(s) - multienzymes (lipase, protease etc.)

Australia - inglés - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium trihydrate, quantity: 86.8 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; microcrystalline cellulose; crospovidone; sodium carbonate; glycerol dibehenate; titanium dioxide; hypromellose; macrogol 6000 - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. ,atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium trihydrate, quantity: 86.8 mg - tablet, film coated - excipient ingredients: sodium carbonate; magnesium stearate; glycerol dibehenate; crospovidone; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000 - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. ,atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 41.44 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: povidone; mannitol; methionine; microcrystalline cellulose; crospovidone; sodium carbonate; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000 - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of nonfatal mi and nonfatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; crospovidone; sodium carbonate; magnesium stearate; mannitol; methionine; titanium dioxide; hypromellose; macrogol 6000 - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of nonfatal myocardial infarction and nonfatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.